Varian’s IDE win makes way for first ever FLASH therapy clinical trial

By Nikita Chaurasia  Date: 2020-10-13

Varian’s IDE win makes way for first ever FLASH therapy clinical trial

U.S.-based radiotherapy technology company, Varian Medical Systems has made it to the headlines for reportedly receiving an IDE (Investigational Device Exemption) from the U.S. Food & Drug Administration.

For the uninitiated, FLASH therapy is an innovative radiation treatment that involves ultra-high dose rates of radiotherapy. The study, named FAST-01, will conduct the investigation using Varian's ProBeam particle accelerator which is apparently modified with a specialized module with FLASH capabilities.

If reports are to be believed, the trial will involve over 10 patients with bone metastases and evaluate parameters such as side-effects, efficacy of the treatment and clinical workflow feasibility. In fact, preclinical trials conducted by Varian suggested that the new technology is significantly faster and causes lesser tissue damage as compared to conventional radiotherapy.

It is to be noted that Varian has supported the FlashForward Cosortium, a 20-member group of institutions from across the globe, that includes experts in translational sciences, radiation oncology and medical physics.

Speaking of the trials, President of Proton Therapy Solutions and Chief Growth Officer at Varian, Kolleen Kennedy, was reported saying that the company’s advancement in FLASH therapy is a testament to their investments and efforts towards improving cancer treatment.

Dr. Deepak Khuntia, Chief Medical Officer and Senior VP of Varian mentioned in a comment that the investigation is vital proof of concept, particularly in deep-seated as well as superficial tumors. It will impart a thorough understanding regarding the operations of FLASH therapy , he added.

Sources close to the matter claim that the patient enrollment in the FAST-01 Feasibility Study is expected to commence by the end of the year 2020.

About Varian Medical Systems

California-headquartered Varian Medical Systems is a radiation oncology treatments and software company and focuses on developing innovative cancer care technologies and solutions.

With over 10,000 employees across 70 locations, the company harnesses advanced technologies such as machine learning, AI (artificial intelligence) and data analytics in order to enhance cancer treatment.

 

Source credits: https://www.prnewswire.com/news-releases/varian-receives-investigational-device-exemption-ide-and-prepares-for-first-ever-clinical-trial-of-flash-therapy-301149339.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

1health to offer two types of COVID-19 testing kits to SkyWest Airlines

By Nikita Chaurasia

Leading Testing as a Service (TaaS) provider, 1health, recently announced that it has partnered with SkyWest Airlines, a SkyWest Inc. subsidiary, to provide two types of COVID-19 tests to the airline’s personnel. Mehdi Maghsoodnia, CEO at 1hea...

FBI to remove backdoors from hacked Microsoft Exchange email servers

FBI to remove backdoors from hacked Microsoft Exchange email servers

By Nikita Chaurasia

Following the recent cyber-attack in the US, a court in Houston has reportedly authorized a new FBI operation to copy and eliminate backdoors from large number of Microsoft Exchange email servers across the country. During this hacking event, the hac...

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...